Kura Oncology, Inc. · NASDAQ:KURA

Kura Oncology — Technical Presentation (December 2025)

14 slides from Kura Oncology's technical presentation, December 2025

  1. Slide 1: Ziftomenib with Venetoclax and Azacitidine in Newly Diagnosed NPM1-m AML: Phase 1b KOMET-007

    Reused with permission from the American Society of Hematology. © 2025 The Authors. All rights reserved. Officially licensed by ASH for distribution via a corporate website by Kura. Ziftomenib in Combination with Venetoclax and Azacitidine in Newly Diagnosed NPM1-m Acute Myeloid Leukemia: Phase 1b R

  2. Slide 2: Ziftomenib Targets the Menin Pathway, a Foundational Target in AML

    Ziftomenib Targets the Menin Pathway, a Foundational Target in AML • NPM1 mutations drive leukemogenesis in ~30% of AML1,2 • Ziftomenib is a potent, highly selective, oral menin inhibitor with clinical activity as both monotherapy and in combination for adults with NPM1-m AML3,4 • Ziftomenib monothe

  3. Slide 3: KOMET-007: Ongoing Phase 1 Combination Trial of Ziftomenib in Newly Diagnosed AML

    KOMET-007: Ongoing Phase 1 Combination Trial of Ziftomenib in Newly Diagnosed AMLa Ziftomenib + Ven/Aza Combination (NCT05735184) Phase 1b: Dose expansion / RP2D determination Adults with RP2D validation: Endpoints: Newly Diagnosed NPM1-m AML Primary Secondary (N=40) Ziftomenib + Ven/Aza Validated 1

  4. Slide 4: KOMET-007: Safety and Efficacy Populations

    KOMET-007: Safety and Efficacy Populations: Newly Diagnosed AML Safety Population 40 Enrolled and treated with • As of Sep 24, 2025, 40 patients with newly Ziftomenib 600 mg QD + Ven/Aza diagnosed NPM1-m AML were enrolled and treated with ziftomenib 600 mg orally No response assessment as of once da

  5. Slide 5: Baseline Characteristics: Newly Diagnosed AML

    Baseline Characteristics: Newly Diagnosed AML NPM1-m, 600 mg n (%) (N=40) Median age, years (range) 75 (53–93) Female 21 (53) Race White 31 (78) Non-White / Other 5 (13) Unknown / Not reported 4 (10) ECOG PS 0 1 (3) 1 16 (40) 2 23 (58) Selected co-mutationsa 26 (65) FLT3 14 (35) IDH1/2 9 (23) Therap

  6. Slide 6: Safety and Tolerability of Ziftomenib with Ven/Aza: TEAEs in ≥25% of Patients

    Safety and Tolerability of Ziftomenib with Ven/Aza: Newly Diagnosed AML TEAEs in ≥25% of Patients All TEAEs Ziftomenib-Related TEAEs n (%) (N=40) (N=40) Any Grade 40 (100) 25 (63) Nausea 16 (40) 9 (23) Vomiting 16 (40) 4 (10) Diarrhea 16 (40) 5 (13) Fatigue 16 (40) 8 (20) Thrombocytopeniaa 15 (38) 8

  7. Slide 7: Safety and Tolerability of Ziftomenib with Ven/Aza: Grade ≥3 TEAEs in ≥10% of Patients

    Safety and Tolerability of Ziftomenib with Ven/Aza: Newly Diagnosed AML Grade ≥3 TEAEs in ≥10% of Patients All Grade ≥3 TEAEs Grade ≥3 Ziftomenib-Related TEAEs n (%) (N=40) (N=40) Grade ≥3 34 (85) 16 (40) Neutropeniaa 15 (38) 8 (20) Thrombocytopeniab 11 (28) 7 (18) Leukopeniac 10 (25) 4 (10) Anemia

  8. Slide 8: Clinical Activity of Ziftomenib with Ven/Aza: Newly Diagnosed AML

    Clinical Activitya of Ziftomenib with Ven/Aza: Newly Diagnosed AML NPM1-m, 600 mg n (%) (N=37) CRc 32 (86) Median time to first CRc, weeks (range) 3.4 (2.4–9.6) ORR 33 (89) CR 27 (73) CRh 2 (5) CRi 3 (8) MLFS 1 (3) PR 0 (0) NR 1 (3) NEb 3 (8) • CR/CRh rates by co-mutated status were consistent with

  9. Slide 9: Molecular MRD Negativity in CRc Responders: Newly Diagnosed AML

    Molecular MRD Negativity in CRc Responders: Newly Diagnosed AML Central MRD Central MRD n/N (%) (Threshold ≤0.1%) (Threshold ≤0.01%) MRD negativity ratea 17/25 (68) 11/25 (44) Median time to first MRD negativity, 9.4 (4.9–22.9) 9.6 (8.4–22.9) weeks (range) Timing of MRD negativityb: By Cycle 1 1/17

  10. Slide 10: Duration of Treatment and Clinical Outcomes: Newly Diagnosed AML

    Duration of Treatment and Clinical Outcomes: Newly Diagnosed AML NPM1-m 010 0 0 01 0 011 After a median follow-up of 26.1 weeks 01 00 0101 0 010 00 (range 1.6–54.1): 01 00 01 00 01 0 01 • Median duration of CR was not reacheda 010 00 01 010 010 01 • Median OS was not reacheda 011 00 • 5 NPM1-m patie

  11. Slide 11: ANC and Platelet Recovery in CRc Responders: Newly Diagnosed AML

    ANC and Platelet Recovery in CRc Responders: Newly Diagnosed AML NPM1-m, 600 mg Median (range) (N=32)a ays to ANC reco ery ≥0.5 × 109/L 36 (1–69) ays to ANC reco ery ≥1.0 × 109/L 37 (1–69) ays to latelet count reco ery ≥50 × 109/L 24 (0–84) ays to latelet count reco ery ≥100 × 109/L 30 (20–77) • Tim

  12. Slide 12: Conclusions

    Conclusions • In the ongoing KOMET-007 study, ziftomenib 600 mg QD combined with Ven/Aza showed high rates of durable morphologic and MRD-negative CR in newly diagnosed NPM1-m AML – 86% CRc (73% CR), with 68% molecular CRc MRD-negativity – Median duration of CRc and median OS were not reached as of

  13. Slide 13: KOMET-017: Phase 3 Ziftomenib Pivotal Newly Diagnosed Combination Studies

    KOMET-017: Phase 3 Ziftomenib Pivotal Newly Diagnosed Combination Studies KOMET-017-NIC: Non-intensive therapya – Ziftomenib + venetoclax/azacitidine combo Two independently Arm A Ziftomenib Primary endpoints Patients powered, registration- Venetoclax + Azacitidine • NPM1-m AML R • CR 1:1 enabling,

  14. Slide 14: Acknowledgments

    Acknowledgments • We would like to thank all the patients, their families, and their caregivers, as well as the KOMET-007 study investigators and their study teams • This study was sponsored by Kura Oncology, Inc., in partnership with Kyowa Kirin group • Medical writing support was provided by Envis

Kura Oncology — Technical Presentation (December 2025) on 6ix